A Phase I, Open Label, Single Center Study Evaluating the Safety and Efficacy of IB-T101 Injection for Treatment of Patients with Advanced Clear Cell Renal Cell Carcinoma
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This is an open label, single center, dose escalation, and dose extension IIT study aimed at evaluating the safety, efficacy, and pharmacokinetics of IB-T101 in adult patients with advanced clear renal cell carcinoma
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Voluntarily join the study, signed informed consent form， willing and able to comply with the study protocol;
• Age ≥18 years old;
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
• Expected survival time of ≥ 3 months;
Locations
Other Locations
China
Tongji hospital, Huazhong University of Science and Technology
RECRUITING
Wuhan
Contact Information
Primary
Bo Liu
liubo0124@163.com
15927168582
Time Frame
Start Date: 2024-12-06
Estimated Completion Date: 2027-12-07
Participants
Target number of participants: 12
Treatments
Experimental: IB-T101 injection treatment group
Related Therapeutic Areas
Sponsors
Leads: Grit Biotechnology